189747-29-3Relevant articles and documents
NITROGEN HETEROCYCLIC COMPOUNDS AND METHODS OF USE
-
Paragraph 1808; 1812; 2049, (2021/06/26)
The present disclosure relates to compounds of formula (I): and pharmaceutically acceptable salts and stereoisomers thereof. The present disclosure also relates to methods of preparing the compounds, compositions comprising the compounds, and methods of using the compounds as inhibitors of receptor tyrosine kinases, in particular oncogenic mutants of ErbB-receptors e.g. in the treatment of cancer.
Tyrosine kinase inhibitors. 12. Synthesis and structure-activity relationships for 6-substituted 4-(phenylamino)pyrimido[5,4-d]pyrimidines designed as inhibitors of the epidermal growth factor receptor
Rewcastle, Gordon W.,Bridges, Alexander J.,Fry, David W.,Rubin, J. Ronald,Denny, William A.
, p. 1820 - 1826 (2007/10/03)
A series of 6-substituted 4-anilinopyrimido[5,4-d]pyrimidines has been prepared and shown to be potent inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR). These compounds are structurally related to the pyrido[3,2-d]
